Doximity, Inc.

Report azionario NYSE:DOCS

Capitalizzazione di mercato: US$4.3b

Doximity Dividendi e riacquisti

Criteri Dividendo verificati 0/6

Doximity non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

9.8%

Rendimento del riacquisto

Rendimento totale per gli azionisti9.8%
Rendimento futuro dei dividendi0%
Crescita dei dividendin/a
Prossima data di pagamento dei dividendin/a
Data di stacco del dividendon/a
Dividendo per azionen/a
Rapporto di remunerazionen/a

Aggiornamenti recenti su dividendi e riacquisti

Recent updates

Aggiornamento narrativa • Sep 05

DOCS: AI Monetization And Clinical Suite Adoption Will Support Higher Earnings Power

Analysts lifted their Doximity fair value estimate from about $36.89 to roughly $45.45, citing revised models that factor in a slightly higher assumed P/E multiple, modestly lower revenue growth, a small uptick in profit margin, and updated views on AI driven monetization following recent price target changes across the Street. Analyst Commentary Recent Street commentary on Doximity shows a wide range of views, but the common thread is that the latest quarter and early AI initiatives are front and center for valuation debates.
Aggiornamento narrativa • Aug 22

DOCS: AI Budget Share And Q1 AI Traction Will Drive Bullish Outlook

Analysts have lifted their Doximity price target from about $28.00 to roughly $29.78. This reflects updated models after Q1 results, differing views on AI monetization, and mixed opinions on how far current AI traction and pharma budget share can support growth amid rising competition and margin pressures.
Aggiornamento narrativa • Aug 08

DOCS: AI Investment Year And Pharma Budget Share Will Shape Fairly Valued Outlook

Analysts have raised Doximity’s fair value estimate from $24.37 to $28.00, reflecting Street research that highlights solid recent results, early traction in AI search, and the potential for the company to capture a larger share of pharma marketing budgets, despite ongoing questions about competition and execution risk. Analyst Commentary Street research on Doximity is split, with some bullish analysts pointing to improving execution and AI traction, while more cautious voices focus on execution risk, competition in healthcare AI, and visibility on longer term growth.
Seeking Alpha • Aug 07

Doximity Jumps On Earnings: Explaining The Outsized Stock Move (Rating Upgrade)

Summary Doximity, Inc. is upgraded to buy as the narrative shifts from stagnation to credible reacceleration, driven by AI engagement and improved revenue guidance. Revenue grew 7% YoY to $156.6M, with FY27 guidance raised to $671–681M, while margins compressed due to intentional reinvestment in AI and sales. AI tools, especially Doximity Ask, are rapidly integrating into physician workflows, positioning DOCS for deeper engagement and future monetization opportunities. DOCS stock valuation sits at a discount to peers on earnings and EBITDA, with the upside hinging on AI-driven engagement translating into sustained revenue growth. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 21

DOCS: Clinical AI Safety Leadership Will Support Higher Future Earnings Power

The analyst fair value estimate for Doximity has been reset from $55.00 to $36.89 after multiple firms trimmed price targets, citing concerns about slower core growth, heavier AI investment weighing on margins, and rising competitive and execution risks. Analyst Commentary Recent Street research on Doximity reflects a reset in expectations around growth, profitability, and competitive positioning, particularly as the company leans into heavier AI investment and faces questions about the durability of its core advertising business.
Aggiornamento narrativa • Jul 07

DOCS: AI Spending And Competitive Pressures Will Test Healthcare Moat And Reengagement Potential

Doximity's analyst price target has been trimmed as fair value and the assumed future P/E move lower, with analysts citing weaker revenue visibility, heavier AI spending, and rising competitive pressures around digital pharma marketing and healthcare AI tools. Analyst Commentary Recent Street research on Doximity points to a more cautious stance, with many firms cutting price targets and revisiting growth expectations after the latest earnings reports and long term guidance.
Aggiornamento narrativa • Jun 23

DOCS: AI Investment Year And Healthcare Moat Set To Support Reengagement

The updated Doximity analyst price target edges up slightly to $25.42, as analysts balance concerns about slower digital advertising growth, tougher competition, and heavier AI investment against a still supportive longer term rationale. This is reflected in a modestly higher fair value and P/E assumption.
Nuova narrativa • Jun 13

High physician usership and impressive AI tools

What I like about Doximity is that there really is a very high viewership / user base of active practicing Physicians in the US and that is not invaluable and definitely could be monetized perhaps more efficiently. I also think that Doximity offers a lot of interesting tools for Physicians a lot of which you’re free and really marketed towards I think Physicians who are more in private practice.
Aggiornamento narrativa • Jun 07

DOCS: Healthcare Moat And AI Investment Year Will Drive Future Engagement

Analyst price targets for Doximity have been reset lower, with the internal fair value estimate moving from $37.77 to $25.15 as analysts factor in slower projected revenue growth, softer profit margins, and a reduced future P/E multiple amid industry wide concerns about digital ad spending, rising competition, and uncertain payoffs from heavier AI investment. Analyst Commentary Street research has turned more cautious on Doximity following its recent results and fiscal 2027 outlook, with many firms cutting price targets and, in several cases, downgrading ratings.
Aggiornamento narrativa • May 23

DOCS: Heavier AI Spending And Competition Will Drive A Cautious Bearish Outlook

Analysts cut the Doximity fair value estimate from $25.00 to $18.00, citing a wave of price target reductions and ratings downgrades that point to slower expected revenue growth, thinner margins, rising AI investment costs, and tougher digital advertising and healthcare IT competition. Analyst Commentary Street research around Doximity has shifted decisively more cautious, with a cluster of downgrades and lower price targets following the most recent earnings and long term outlook.
Aggiornamento narrativa • May 09

DOCS: AI Suite And Platform Stickiness Will Support Higher Future Earnings Power

Analysts trimmed their Doximity fair value estimate to $55.00 from $56.00, reflecting reduced revenue growth assumptions, partly offset by expectations for slightly higher profit margins and a marginally richer future P/E multiple following a series of recent price target cuts and mixed rating changes across the Street. Analyst Commentary Recent Street research on Doximity has been mixed, with a cluster of price target cuts and rating changes alongside a handful of more constructive views.
Aggiornamento narrativa • Apr 21

DOCS: Healthcare Moat And AI Tools Will Support Future Engagement

The updated analyst price target for Doximity reflects a modest fair value reduction of about $1.77 per share, as analysts factor in weaker revenue growth visibility highlighted in several recent downgrades and target cuts, while also noting resilient margins and interest in the company’s AI tool suite. Analyst Commentary Recent research on Doximity presents a mix of optimism around the platform and its AI tools, alongside concern about the visibility and durability of revenue growth.
Aggiornamento narrativa • Apr 07

DOCS: Rebased Sentiment And Healthcare Moat Will Support Future Engagement

The updated analyst price target for Doximity moves from about $63.57 to roughly $39.55. This reflects lower modeled revenue growth, profit margins and future P/E multiples, even as several firms highlight the platform's network effects, AI tools and healthcare marketing traction as key long term strengths.
Aggiornamento narrativa • Mar 24

DOCS: AI Tools And Buybacks Will Shape A Cautious Balanced Outlook

Analysts held the Doximity fair value estimate steady at $25.00, while modestly adjusting assumptions after mixed but generally constructive price target moves that highlight interest in the platform's AI tools, network effects, and healthcare marketing exposure. Analyst Commentary Recent Street research on Doximity reflects a split view, with some firms highlighting the medical AI tool suite, network effects and healthcare marketing exposure, while others reset expectations through lower price targets and more neutral ratings.
Aggiornamento narrativa • Mar 09

DOCS: AI Tools And Share Buybacks Will Drive Shares Higher

Doximity's updated fair value estimate has decreased to $56.00 from $68.90, reflecting analysts' reduced price targets from several firms, alongside ongoing support for the company's AI tools and healthcare marketing position. Analyst Commentary Street research on Doximity has been mixed, but there is a clear cluster of bullish analysts who see support for the story in healthcare marketing, AI tools and the company’s position with U.S. physicians.
Aggiornamento narrativa • Feb 23

DOCS: AI Suite And Share Buybacks Will Shape A More Balanced Outlook

The analyst fair value estimate for Doximity has been revised to $25 from $50, reflecting a wave of reduced price targets across several firms, even as some analysts highlight potential from the company’s AI tools and broader healthcare marketing ecosystem. Analyst Commentary Recent research on Doximity shows a split tape, with some firms cutting price targets sharply while others highlight potential upside tied to the company’s tools and healthcare marketing position.
Aggiornamento narrativa • Feb 09

DOCS: Pharma Ad Shift And Share Buybacks Will Drive Shares Higher

Analysts have reduced their Doximity fair value estimate from about US$83 to roughly US$69. This reflects updated expectations for more moderate revenue growth, slightly lower profit margins and a reduced future P/E multiple, even as several firms highlight the company’s strong position in digital healthcare marketing and its expanding product tools.
Articolo di analisi • Feb 06

Doximity, Inc.'s (NYSE:DOCS) Popularity With Investors Under Threat As Stock Sinks 27%

To the annoyance of some shareholders, Doximity, Inc. ( NYSE:DOCS ) shares are down a considerable 27% in the last...
Aggiornamento narrativa • Jan 26

DOCS: Rebased Sentiment And Strong Moat Will Support Future Engagement

Narrative Update on Doximity The analyst fair value estimate for Doximity has been adjusted from US$65.25 to about US$63.57 as analysts factor in lower target prices, along with continued confidence in the company's moat, market share gains, and higher reported ROI compared with other digital healthcare marketing platforms. Analyst Commentary Recent research on Doximity highlights a mix of optimism and caution as analysts update ratings and price targets while reassessing growth, execution, and risk pricing.
Aggiornamento narrativa • Jan 11

DOCS: Rebased Sentiment And Budget Shifts Will Support Stronger Engagement

Our updated analyst price target framework for Doximity moves fair value from US$71.11 to US$65.25 as analysts recalibrate growth, discount rate and forward P/E assumptions, while still pointing to strengthening platform engagement and expanding tools such as OpenEvidence, as well as what several describe as a defensible competitive position in healthcare professional marketing. Analyst Commentary Recent Street research on Doximity reflects a mix of optimism around the core franchise and its tools such as OpenEvidence, alongside a more cautious reset on valuation and competitive risk.
Aggiornamento narrativa • Dec 26

DOCS: Budget Flush And Pharma Ad Shift Will Drive Shares Higher

We modestly raised our Doximity price target to $83.00 per share from $62.00, as analysts highlight improving long term growth visibility, accelerating video driven revenue momentum, and an increasingly compelling risk reward profile following the recent pullback, despite ongoing debate around pharma digital ad trends. Analyst Commentary Bullish analysts are increasingly highlighting Doximity as a high conviction idea following the post earnings selloff, pointing to a more attractive entry point relative to its vertical software peers.
Aggiornamento narrativa • Dec 12

DOCS: Budget Flush And Ad Shift Will Drive Shares Higher

Analysts have lifted their Doximity fair value estimate to $83.00 from $78.58, reflecting stronger expected revenue growth and improving long term growth visibility, which they believe more than offset lower margin assumptions and a higher required return. Analyst Commentary Bullish analysts highlight that the recent pullback in Doximity shares has created a compelling entry point, with the stock now trading at what they view as an unjustified discount to the broader vertical software peer group.
Articolo di analisi • Nov 14

Doximity, Inc. (NYSE:DOCS) May Have Run Too Fast Too Soon With Recent 26% Price Plummet

The Doximity, Inc. ( NYSE:DOCS ) share price has fared very poorly over the last month, falling by a substantial 26...
Aggiornamento narrativa • Nov 01

DOCS: Pharma Advertising Shift And AI Expansion Will Drive Measured Opportunity And Risks

Analysts have modestly increased their price target for Doximity, raising the estimate from $70.72 to $71.11 per share. They cite stronger revenue momentum, which is supported by recent upgrades and expectations for higher provider-driven growth.
Aggiornamento narrativa • Oct 18

AI Integration And Telehealth Expansion Will Transform The Healthcare Industry

Analysts have raised their price target for Doximity from $69.50 to $70.72. They cited slightly improved profit margin forecasts and increased confidence in the company’s platform engagement as advertising trends evolve.
Aggiornamento narrativa • Oct 04

AI Integration And Telehealth Expansion Will Transform The Healthcare Industry

Doximity's analyst price target has increased from $68.67 to $69.50 per share. This change reflects analysts' positive view on strong business momentum, promising AI initiatives, and a conservative outlook for fiscal 2026 revenue growth.
Aggiornamento narrativa • Sep 13

AI Integration And Telehealth Expansion Will Transform The Healthcare Industry

Doximity’s price target was raised modestly to $68.67 as analysts pointed to robust Q1 results, AI-driven strategy enhancements, and conservative guidance as drivers of sustained business momentum. Analyst Commentary Bullish analysts cite strong Q1 results and upwardly revised guidance as evidence of solid business momentum.
Articolo di analisi • Sep 02

At US$67.94, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?

Doximity, Inc. ( NYSE:DOCS ) saw a significant share price rise of 32% in the past couple of months on the NYSE...
Articolo di analisi • Aug 15

We Think Doximity's (NYSE:DOCS) Profit Is Only A Baseline For What They Can Achieve

NYSE:DOCS 1 Year Share Price vs Fair Value Explore Doximity's Fair Values from the Community and select yours When...
Aggiornamento narrativa • Aug 10

AI Integration And Telehealth Expansion Will Transform The Healthcare Industry

Doximity’s fair value outlook has improved as reflected by a higher consensus price target, despite a notable contraction in net profit margin and a rising future P/E multiple signaling higher growth expectations. What's in the News Doximity provided revenue guidance for FY26 of $628–636 million and Q2 FY26 of $157–158 million.
Articolo di analisi • Jul 08

Getting In Cheap On Doximity, Inc. (NYSE:DOCS) Is Unlikely

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...
Articolo di analisi • Jun 23

With EPS Growth And More, Doximity (NYSE:DOCS) Makes An Interesting Case

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Articolo di analisi • May 17

At US$52.56, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?

Let's talk about the popular Doximity, Inc. ( NYSE:DOCS ). The company's shares saw significant share price movement...

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di DOCS siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di DOCS siano aumentati.

Rendimento dei dividendi rispetto al mercato

Doximity Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di DOCS rispetto al mercato?
SegmentoRendimento dei dividendi
Azienda (DOCS)n/a
Fondo del 25% del mercato (US)1.4%
Top 25% del mercato (US)4.1%
Media del settore (Healthcare Services)1.2%
Analista previsionale (DOCS) (fino a 3 anni)0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di DOCS rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di DOCS rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di DOCS per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché DOCS non ha segnalato alcun pagamento.

Scoprire le società che pagano dividendi forti

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/09/10 08:14
Prezzo dell'azione a fine giornata2026/09/10 00:00
Utili2026/06/30
Utili annuali2026/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Doximity, Inc. è coperta da 26 analisti. 20 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Vikram KesavabhotlaBaird
Glen SantangeloBarclays
Nisala WeerasuriyaBerenberg